Retatrutide has emerged as a new medication in the fight against obesity. This groundbreaking drug, categorized as a dual GLP-1 and GIP receptor agonist, demonstrates promising results in research studies. By boosting these receptors, Retatrutide controls cravings, {promotesenergy expenditure, and u